Boston Scientific completes $3.7B acquisition of Axonics; enters sacral neuromodulation market

BOSTON SCIENTIFIC CORP

Purchase price $71/share, equity value $3.7B, enterprise value $3.3B net of cash.
Deal expected to be immaterial to adjusted EPS in 2024-2025, accretive thereafter.
Adds Axonics' sacral neuromodulation portfolio for urinary/bowel dysfunction to Urology unit.
GAAP basis less accretive due to amortization and acquisition-related charges.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.